Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In hepatocellular carcinoma (HCC) patients, the proportion of responders to immune-checkpoint inhibitors remains low despite initial enthusiasm.
Macek Jilkova et al. 2022 Current Opinion in Oncology 34(2): 155-160
Specific inflammatory mechanisms induced by NASH may result in limited efficacy of immunotherapy compared with viral HCC.
Macek Jilkova et al. 2022 Current Opinion in Oncology 34(2): 155-160
see also:
Anti-PD-1 antibodies / PD-1 inhibitors & Hepatocellular Carcinoma (HCC)
…